Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 1999

View Archived Issues

Priority review status assigned to Rapamune immunosuppressive therapy

Pediatric use of Maxipime approved by the FDA

Roberts and Yuhan enter distribution agreement for Agrylin in Korea

Alza launches Ditropan XL in the U.S.

GABA-A ligands useful for treating CNS disorders

Tachykinin antagonists claimed by HMR for asthma, cough, bronchitis and pain

New series of NHE inhibitors in development at Synthelabo

Enzon initiates phase III trials of PEG-Intron/Rebetol combination therapy for hepatitis C

Improved salts of ACE inhibitors prepared at NicOx

Bayer describes production and use of 2,9-disubstituted purin-6-ones

Schering discloses new leukotriene antagonists particularly useful as dermatological products

Genetics Kenkyusho and Yamanouchi to continue development of joint venture products separately

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Kirin to restart clinical trials of TPO

Clinical trials for Japanese immunosuppressant begin in Europe

KRH-594, a new angiotensin antagonist, evaluated in animal models of hypertension

Genome Therapeutics achieves milestone in asthma alliance with Schering-Plough

Cantab completes acquisition of drug addiction programs from ImmuLogic

New immunomodulator LK-423 possesses unique pharmacological properties

Boehringer Ingelheim seeks E.U. marketing approval for non-CFC respiratory device

Cephalon's narcolepsy treatment launched in Ireland

Moderate drinking reported to protect against ischemic stroke

Ontogen completes phase I study of MDR-modulating compound

Ontogeny enters diabetes research collaboration with Becton Dickinson

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...